9 Meters Biopharma Inc. (INNT) Stock Price, Quote, News and Overview
NASDAQ:INNT - Nasdaq -
INNT Quote, Performance and Key Statistics
0.56
-0.14 (-20.23%)
The current stock price of INNT is 0.56 null. In the past month the price increased by 19.15%. In the past year, price decreased by -64.33%.
About INNT
Company Profile
Innovate Biopharmaceuticals, Inc. is a clinical stage biotechnology company. It focused on developing novel medicines for autoimmune/ inflammatory disease. The company's pipeline includes drug candidates for celiac disease, an unmet need, and ulcerative colitis. Its products includes INN-202 for the treatment of Celiac Disease with fast track designation, INN-108 for Inflammatory Bowel Disorders, mild to moderate Ulcerative Colitis and a GI orphan disease in a convenient liquid formulation, INN-329 for Magnetic Resonance Cholangiopancreatography which are in clinical stages. Innovate Biopharmaceuticals Inc., formerly known as Monster Digital, Inc., is based in SIMI VALLEY, United States.
Company Info
9 Meters Biopharma Inc.
8480 HONEYCUTT ROAD SUITE 120
RALEIGH NC 27615
CEO: Sandeep Laumas
Phone: 919-275-1933
9 Meters Biopharma Inc. / INNT FAQ
What is the stock price of 9 Meters Biopharma Inc. today?
The current stock price of INNT is 0.56 null. The price decreased by -20.23% in the last trading session.
What is the ticker symbol for 9 Meters Biopharma Inc. stock?
The exchange symbol of 9 Meters Biopharma Inc. is INNT and it is listed on the Nasdaq exchange.
On which exchange is INNT stock listed?
INNT stock is listed on the Nasdaq exchange.
What is 9 Meters Biopharma Inc. worth?
9 Meters Biopharma Inc. (INNT) has a market capitalization of 23.14M null. This makes INNT a Nano Cap stock.
What are the support and resistance levels for 9 Meters Biopharma Inc. (INNT) stock?
9 Meters Biopharma Inc. (INNT) has a support level at 0.46 and a resistance level at 0.61. Check the full technical report for a detailed analysis of INNT support and resistance levels.
Should I buy 9 Meters Biopharma Inc. (INNT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INNT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INNT, evaluating the profitability, health, valuation and growth aspects
- 9 Meters Biopharma Inc. (INNT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 9 Meters Biopharma Inc. (INNT) Sales and EPS estimates to see what analysts future expectations are.
- 9 Meters Biopharma Inc. (INNT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 9 Meters Biopharma Inc. (INNT) Insider and Institutional Ownership to learn about the owners and their transactions.
- 9 Meters Biopharma Inc. (INNT) Stock Chart to make your own analysis
- 9 Meters Biopharma Inc. (INNT) Latest news and press-releases to stay up to date.
Does 9 Meters Biopharma Inc. (INNT) stock pay dividends?
INNT does not pay a dividend.
What is the Price/Earnings (PE) ratio of 9 Meters Biopharma Inc. (INNT)?
9 Meters Biopharma Inc. (INNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.6).
INNT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to INNT. When comparing the yearly performance of all stocks, INNT is a bad performer in the overall market: 85.55% of all stocks are doing better.
INNT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INNT. Both the profitability and financial health of INNT have multiple concerns.
INNT Financial Highlights
Over the last trailing twelve months INNT reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS increased by 91.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -510.66% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
INNT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 100% to INNT. The Buy consensus is the average rating of analysts ratings from 1 analysts.